From the ∗Department of Infectious Diseases, Los Angeles Medical Center, Southern California Permanente Medical Group, Los Angeles
†Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA
‡Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, AL
§Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA
¶Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL
This work was supported by the Regional Research Committee of Kaiser Permanente Southern California (grant number KP-RRC-20201006).
Conflict of Interest and Sources of Funding: J.J.C. and Q.C. have no conflicts of interest to declare. R.C.H. has received funding from Gilead for unrelated research. J.D.-O. has funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development for unrelated research. K.J.B. has received funding from Gilead, Dynavax, GlaxoSmithKline, Moderna, and Pfizer for unrelated research.
Conference Presentations: Oral abstract presentation at CROI 2022.
Correspondence: Katia J. Bruxvoort, PhD, MPH, 1666 University Boulevard, Birmingham, AL 35233. E-mail: [email protected].
Received for publication February 18, 2022, and accepted April 16, 2022.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (http://www.stdjournal.com).
